Diabetes Vasc Dis Res (2011) 8(2):11724
Ueda P, Soderling J, Wintzell V, Svanstrom H, Pazzagli L, Eliasson B, et al
The Powerhouse Ingredients
Mechanisms reported in the literature include: GLP-1 receptor activation Stimulates glucose-dependent insulin release Supports appetite regulation and satiety signaling Slows gastric emptying GIP receptor activation Augments insulin secretion Associated with -cell support and improved nutrient handling Glucagon receptor activation Linked to increased energy expenditure Promotes hepatic lipid mobilization and oxidation Clinical Research Evidence In a published Phase 2 randomized trial, retatrutide produced dose-dependent reductions in body weight, with the highest dose associated with up to approximately 24% mean body-weight reduction at 48 weeks , alongside improvements in cardiometabolic markers
Patients who want to reach their ideal body weight before surgery
Possible improvement in overall health markers related to treating obesity and long-term weight maintenance